47 results on '"Nelson, Michelle H."'
Search Results
2. Supplementary Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
3. Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
4. Data from The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
5. Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cell therapy
6. Supplemental Figure S4 from Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling
7. Supplemental Figure S3 from Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling
8. Supplementary Data from IL6 Fuels Durable Memory for Th17 Cell–Mediated Responses to Tumors
9. Supplemental Figure S5 from Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling
10. Supplementary Data from IL6 Fuels Durable Memory for Th17 Cell–Mediated Responses to Tumors
11. Data from IL6 Fuels Durable Memory for Th17 Cell–Mediated Responses to Tumors
12. Supplemental Figure Legend from Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling
13. Data from IL6 Fuels Durable Memory for Th17 Cell–Mediated Responses to Tumors
14. The Bispecific Tumor Antigen-Conditional 4–1BB x 5T4 Agonist, ALG.APV-527, Mediates Strong T-Cell Activation and Potent Antitumor Activity in Preclinical Studies
15. Augmenting TCR signal strength and ICOS costimulation results in metabolically fit and therapeutically potent human CAR Th17 cell therapy
16. Abstract 3434: APVO442 is a distinct PSMA x CD3 targeted bispecific candidate designed to optimize T cell fitness and distribution to solid tumors
17. Abstract LB173: APVO603: A dual 4-1BB and OX40 bispecific approach utilizing ADAPTIRTMtechnology designed to deliver a conditional T cell/NK response against solid tumors
18. Abstract LB172: APVO442: A bispecific T cell-engaging candidate utilizing the ADAPTIR-FLEXTMplatform technology with unique properties designed for optimal tumor distribution and cytotoxic response against PSMA-expressing solid tumors
19. Th17 Cells in Cancer
20. IL6 Fuels Durable Memory for Th17 Cell–Mediated Responses to Tumors
21. Identification of human CD4 + T cell populations with distinct antitumor activity
22. RNA binding protein PCBP1 is an intracellular immune checkpoint for shaping T cell responses in cancer immunity
23. Identification of human CD4+ T cell populations with distinct antitumor activity
24. RNA-Binding Protein PCBP1/hnRNP E1 is an Intracellular Checkpoint for Shaping Effector Versus Regulatory T Cells in Immunity and Cancer
25. Human CD26high T cells elicit tumor immunity against multiple malignancies via enhanced migration and persistence
26. PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells
27. PI3Kδ inhibition supports memory T cells with enhanced antitumor fitness
28. Platelets subvert T cell immunity against cancer via GARP-TGFβ axis
29. β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity
30. Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer
31. Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion
32. A feasibility and safety study of vaccination with Poly-ICLC and peptide-pulsed dendritic cells in patients with advanced pancreatic adenocarcinoma.
33. Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8+ T cells without host preconditioning
34. Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic
35. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling
36. The Inducible Costimulator Augments Tc17 Cell Responses to Self and Tumor Tissue
37. Harnessing the Microbiome to Enhance Cancer Immunotherapy
38. Novel immunotherapies for hematologic malignancies
39. Th17 Cells in Cancer: The Ultimate Identity Crisis
40. Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling
41. Rapid clearance of herpes simplex virus type 2 by CD8+ T cells requires high level expression of effector T cell functions
42. Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine
43. Herpes simplex virus (HSV)-specific T cells activated in the absence of IFN-gamma express alternative effector functions but are not protective against genital HSV-2 infection
44. RNA repair restores hemoglobin expression in IVS2–654 thalassemic mice
45. Effector function and efficacy of CD8+ T cells activated in the absence of IFN‐γ
46. Arginine-Rich Peptide Conjugation to Morpholino Oligomers: Effects on Antisense Activity and Specificity
47. Cellular Uptake of Antisense Morpholino Oligomers Conjugated to Arginine-Rich Peptides
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.